Trevi Therapeutics, Inc.
TRVITrevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduvio, an investigational oral therapy for chronic cough.
Earnings
Next report
Aug 6, 2026 (In 1 week)Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduvio, an investigational oral therapy for chronic cough. The company targets high unmet medical needs in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. Its core value proposition centers on a dual-action mechanism that modulates opioid receptors to suppress the cough reflex while mitigating abuse potential.
Clinical-stage developer with positive Phase 2b data in IPF-related cough and Phase 2a data in refractory chronic cough, holding worldwide commercial rights.
Questions, answered.
- What is Trevi Therapeutics, Inc.'s market cap?
- Trevi Therapeutics, Inc. (TRVI) has a market capitalization of $2.6B and trades on NASDAQ.
- Who are Trevi Therapeutics, Inc.'s competitors?
- Trevi Therapeutics, Inc.'s key competitors include Merck & Co., Inc., Savara Inc., United Therapeutics Corp, and others. These companies compete in similar markets and product categories.
- Who does Trevi Therapeutics, Inc. partner with?
- Trevi Therapeutics, Inc.'s notable partners include Keenova Therapeutics plc, Par Health, GSK plc, and others.
- Where is Trevi Therapeutics, Inc. headquartered?
- Trevi Therapeutics, Inc. is headquartered in United States of America and employs approximately 25 people. It has been publicly traded since 2019.